抗IL-23单抗QX004N治疗银屑病的随机临床试验
该随机临床试验分两部分:1a期为健康受试者单次递增剂量试验,1b期为中国5中心中重度斑块状银屑病患者双盲多剂量递增试验。QX004N呈线性药代动力学且耐受良好,第12周PASI 75及第16周PASI 90在150mg、300mg、600mg队列均为100%,显著高于安慰剂组的33.3%。
要点
- QX004N在健康受试者与银屑病患者中耐受良好,多为轻中度不良事件。
- 150mg、300mg、600mg队列第12周PASI 75与第16周PASI 90均为100%。
- 安慰剂队列PASI 75为33.3%,QX004N疗效显著优于安慰剂。
核心结论
- QX004N耐受良好,在中重度斑块状银屑病患者中疗效优于安慰剂。
研究设计与样本
- 随机临床试验分两部分:1a期为首次人体单次递增剂量试验,纳入55名健康受试者。
- 1b期为双盲多剂量递增试验,在中国5个中心纳入30例中重度斑块状银屑病患者。
- 1a期按4:1随机接受单次皮下QX004N(10mg至600mg)或安慰剂。
- 1b期按4:1随机接受QX004N 150mg、300mg、600mg或安慰剂,每2周一次。
主要发现
- 1a期55名健康受试者平均(SD)年龄35.9(6.0)岁,30名(54.5%)为女性。
- 1b期QX004N组24例中19例(79.2%)为男性,平均(SD)年龄41.4(7.5)岁。
- QX004N呈线性药代动力学,多数不良事件为轻中度,未报告药物相关严重不良事件。
- 150mg、300mg、600mg队列第12周PASI 75与第16周PASI 90比例均为100%,安慰剂队列为33.3%。
- 3个QX004N队列中IGA评分0或1的最大比例为100%。
关键数值与推荐
- 1b期主要疗效终点为第12周达到PASI 75的患者比例。
- 150mg、300mg、600mg队列第12周PASI 75及第16周PASI 90均为100%,安慰剂队列PASI 75为33.3%。
- 3个QX004N队列IGA评分0或1的最大比例均为100%。
临床怎么用
- QX004N每2周皮下给药在150mg至600mg剂量下显示良好耐受性与显著疗效,支持后续临床开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Psoriasis is a chronic, immune-mediated skin disease with an unmet need for biologic treatment options. OBJECTIVE: To assess the safety, pharmacokinetics, and efficacy of QX004N in healthy individuals and patients with moderate to severe plaque psoriasis in China. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was composed of 2 parts. Part 1 was a first-in-human, single-ascending-dose, phase 1a clinical trial conducted from November 2, 2021, to January 16, 2023. Part 2 was a double-blind, multiple dose-escalation, phase 1b clinical trial conducted from February 15, 2023, to January 5, 2024, at 5 clinical centers in China, involving patients with moderate to severe plaque psoriasis. INTERVENTIONS: In part 1, healthy participants in each cohort were assigned in a 4:1 ratio to receive a single subcutaneous injection of QX004N (ranging from 10 mg to 600 mg) or placebo. In part 2, patients in each cohort were assigned in a 4:1 ratio to receive QX004N or placebo at doses of 150 mg, 300 mg, and 600 mg once every 2 weeks. MAIN OUTCOMES AND MEASURES: For part 1, the primary outcome was the safety of a single dose of QX004N in healthy participants, and the secondary outcome was the pharmacokinetic profile. For part 2, the primary efficacy end point was the proportion of patients achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) by week 12; other efficacy end points were considered secondary. RESULTS: The phase 1a clinical trial (part 1) enrolled 55 healthy participants (mean [SD] age, 35.9 [6.0] years; 30 [54.5%] female), and the phase 1b clinical trial (part 2) enrolled 30 patients with moderate to severe plaque psoriasis. The mean (SD) age of QX004N-treated participants in part 2 was 41.4 (7.5) years, and 19 of 24 QX004N-treated participants (79.2%) were male. The mean (SD) age of the placebo cohort in part 2 was 35.3 (8.4) years, and 5 of 6 placebo-treated participants (83.3%) were male. QX004N exhibited linear pharmacokinetics and was tolerated well in both healthy participants and patients with psoriasis. Most adverse events were mild to moderate in severity, with no drug-related serious adverse events reported. The proportion of patients receiving QX004N who achieved PASI 75 at week 12 and PASI 90 (90% improvement in PASI) at week 16 in the 150-mg, 300-mg, and 600-mg cohorts was 100%, significantly higher than that in the placebo cohorts (33.3%). The maximum proportion of patients achieving Investigator's Global Assessment score of 0 or 1 was 100% in the 3 QX004N cohorts. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, QX004N was well tolerated and demonstrated superior efficacy compared to placebo in patients with moderate to severe plaque psoriasis. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: CTR20212313 and CTR20223457.
引用
- Li X, Li B, Yang D, et al. Safety and Efficacy of Anti-IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2025. PMID: 39661362. doi:10.1001/jamadermatol.2024.5059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。